Amgen Inc. (NASDAQ:AMGN)‘s stock had its “outperform” rating reiterated by analysts at BMO Capital Markets in a research note issued to investors on Thursday. They presently have a $190.00 price objective on the medical research company’s stock. BMO Capital Markets’ target price suggests a potential upside of 8.70% from the stock’s current price.
A number of other equities analysts also recently weighed in on AMGN. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Credit Suisse Group AG set a $206.00 price target on Amgen and gave the stock a “buy” rating in a research report on Saturday, September 17th. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target for the company in a research report on Wednesday, August 3rd. Robert W. Baird reaffirmed an “outperform” rating and set a $157.00 price target on shares of Amgen in a research report on Friday, August 26th. Finally, Citigroup Inc. upped their price target on Amgen from $165.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 29th. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $184.56.
Amgen (NASDAQ:AMGN) opened at 174.80 on Thursday. The company has a market cap of $130.81 billion, a price-to-earnings ratio of 17.89 and a beta of 0.87. The company’s 50-day moving average is $172.09 and its 200-day moving average is $160.08. Amgen has a 12 month low of $130.09 and a 12 month high of $176.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. During the same period in the previous year, the firm earned $2.57 EPS. Amgen’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen will post $11.36 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were issued a dividend of $1.00 per share. This represents a $4.00 annualized dividend and a dividend yield of 2.29%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 40.90%.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Valley National Advisers Inc. raised its stake in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock valued at $109,000 after buying an additional 33 shares during the period. Glassman Wealth Services raised its stake in Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock valued at $110,000 after buying an additional 600 shares during the period. Oakworth Capital Inc. raised its stake in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Integrated Wealth Management raised its stake in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock valued at $141,000 after buying an additional 3 shares during the period. Finally, Delta Asset Management LLC TN raised its stake in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock valued at $155,000 after buying an additional 85 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.